Merrimack Pharmaceuticals, Inc.

The Johns Hopkins University

Ipsen Biopharm Limited

Bart S Hendriks

Thomas Joseph Wickham

Helen Lee

Daniel F Gaddy

Elena Geretti

Joseph G Reynolds

Dmitri B Kirpotin

Daryl C Drummond

Samuel V Agresta

Kenneth J Olivier, Jr

Stephan Klinz

Kam W Leong

Hai-Quan Mao

Victor Mandla Moyo

Jonathan Basil Fitzgerald

Eliel Bayever

Sarah F Blanchette

Ashish Kalra

Michael F Haller

Christopher W Espelin

Kevin Y Lin

Samuel Agresta

Thomas Wickham

Dmitiri B Kirpotin

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

Compositions and methods for non-invasive imaging

Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Combination therapy for treating HER2-positive cancers

Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.

Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

The present invention relates to compositions and methods for delivery of nucleic acids. In particular, the invention provides a polymeric delivery formulation including a nucleic acid to be transfected into a host cell, formulated in a biodegradable polymer having phosphorous-based linkages.

Polymers for delivery of nucleic acids

Growing community of inventors

Belmont, MA, United States of America

Bart S Hendriks